Consequently, tocilizumab (TCZ), a humanized anti-IL-6 receptor (IL-6R) monoclonal antibody (mAb) against the alpha chain of IL-6R, which prevents binding of IL-6 to membrane and soluble IL-6R, was developed and has been licensed for the treatment of RA [14]. The gene discussed is IL6R; the disease is rheumatoid arthritis.